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ABSTRACT
Background: Angiogenesis, the growth of new blood vessels, plays an impor-
tant role in tumor growth and metastasis. Both cetuximab and endostatin have been 
found to reduce the expression of endothelial-stimulating growth factors such as vas-
cular endothelial growth factor (VEGF) and interleukin (IL)-8. However, the effects 
of cetuximab alone or in combination with endostatin on human lung adenocarcinoma 
cell growth remain unclear.
Objective: The aim of this study was to evaluate the cellular and molecular 
effects of cetuximab alone and in combination with endostatin on human lung adeno-
carcinoma cell lines H1299, SPC-A1, and H460 in vitro.
Methods: The epidermal growth factor receptor (EGFR) status of a panel of 
human lung adenocarcinoma cell lines was characterized using Western blot analysis. 
We used a modified tetrazolium salt assay to evaluate the growth-inhibitory effects of 
cetuximab and endostatin alone and in combination on the cell lines. We also deter-
mined the effects of these 2 drugs on VEGF and IL-8 expression using enzyme-linked 
immunosorbent assay (ELISA) and Western blot analysis. Cells were treated for 4 days 
with cetuximab 12.5 μg/mL, endostatin 25 μg/mL, or cetuximab 12.5 μg/mL + endo- 
statin 25 μg/mL. Untreated cells cultured for 4 days served as controls.
Results: EGFR expression in the H1299 cells was higher than in the SPC-A1 
and H460 cells. Varying concentrations of cetuximab alone were associated with a 
significant growth-inhibitory effect on all 3 cell lines in a dose-dependent manner 
after 4 days of exposure compared with controls (all, P < 0.05). Compared with con- 
trols, varying concentrations of endostatin alone were not associated with significant 
inhibition of cell growth in any of the 3 cell lines. The inhibitory ratio of cetuximab + 
endostatin at varying concentrations was significantly greater than that of cetuximab 
alone (all, P < 0.05). On ELISA, either drug alone was associated with significant 
reductions in secreted VEGF and IL-8 in the H1299, SPC-A1, and H460 cell lines 
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(all, P < 0.05), with the exception of IL-8 concentration in the H460 cells. Mean (SD) 
VEGF expression with combination treatment in the H1299 and SPC-A1 cell lines 
(687 [21] and 629 [23] pg/mL, respectively) was significantly lower than with cetuxi- 
mab alone (878 [31] and 708 [20] pg/mL; both, P < 0.001); in the H460 cell line, 
combination treatment was not associated with a significant further reduction in 
VEGF expression. IL-8 concentrations with cetuximab in the H1299, SPC-A1, and 
H460 cell lines were 628 (20), 484 (29), and 532 (28) pg/mL, respectively, while the 
IL-8 concentrations with the combination treatment were 516 (20), 480 (18), and 467 
(30) pg/mL. An enhanced effect of endostatin on IL-8 was observed in the H1299 and 
H460 cell lines (P < 0.001 and P = 0.018, respectively); however, no enhanced effect 
in the SPC-A1 line was observed. Similar results for VEGF and IL-8 expression were 
found using Western blot analysis.
Conclusions: The results from this in vitro study suggest that cetuximab 
treatment might both inhibit human lung adenocarcinoma cell line growth and 
reduce the expression of VEGF and IL-8, which are the biomarkers of angiogenesis. 
Endostatin was not associated with inhibition of human lung adenocarcinoma cell 
line growth directly. Findings with the combination of cetuximab + endostatin sug-
gest that endostatin might enhance the antiangiogenic and antitumor activity of 
cetuximab through an apparent effect on VEGF expression and, to a lesser degree, on 
IL-8 expression. (Curr Ther Res Clin Exp. 2009;70:116–128) © 2009 Excerpta Medica 
Inc.
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INTRODUCTION
Angiogenesis is a crucial factor in increased invasiveness and widespread metastases 
in a variety of human neoplasms.1 Such tumors overexpress the angiogenic factors, 
including basic fibroblast growth factor (bFGF), vascular endothelial growth fac- 
tor (VEGF), interleukin (IL)-8, and platelet-derived growth factor (PDGF), which 
are important in regulating tumor–host interactions that result in tumor 
neovascularization.
The transforming growth factor-α (TGF-α)–epidermal growth factor receptor 
(EGFR) signaling pathway plays an important role in the development and progres-
sion of human epithelial cancers.2 Overexpression of EGFR has been detected in many 
human carcinomas, including non–small cell lung cancer (NSCLC),2–4 and is generally 
an indicator of poor prognosis.5 Recently, the link between the EGFR signaling path-
way and angiogenesis was identified. Both EGF and TGF-α, ligands for EGFR, have 
been reported to induce angiogenesis.6–8
Targeted biologic therapies that selectively interfere with tumor angiogenesis could 
improve survival among patients with lung cancer. The interest in EGFR-targeting 
drugs resulted in the development of cetuximab (also known as C225) in the past 
5 years. Cetuximab is a chimeric immunoglobulin G1 monoclonal antibody that binds 
to EGFR with high specificity and with a higher affinity than EGFs, thereby blocking 
ligand-induced phosphorylation of EGFR and strongly inhibiting EGFR-dependent 
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tumor angiogenesis.9 Endostatin is another tumor-derived angiogenesis inhibitor and 
is the first endogenous inhibitor of angiogenesis to be identified in a matrix protein. 
It is a 20-kDa internal fragment of the carboxyterminus of collagen XVIII,10–12 spe-
cifically inhibiting the proliferation and migration of endothelial cells and inducing 
their apoptosis with no direct cytotoxic effect on tumor cells.10,13–15
Based on a PubMed search (key terms: endostatin, lung neoplasms, and cetuximab; 
years: 1974–2008), little information is available about the effects of cetuximab in 
combination with endostatin on human lung adenocarcinoma cells. The aim of this 
study was to investigate the growth-inhibitory effects of cetuximab alone and in com-
bination with endostatin in the human lung adenocarcinoma cell lines H1299, SPC-
A1, and H460 in vitro. VEGF and IL-8 expression in these cell lines when treated 
with the blocking anti-EGFR cetuximab and angiogenesis inhibitor endostatin were 
also investigated.
MATERIALS AND METHODS
Cell Cultures
Human lung adenocarcinoma cell lines H1299, SPC-A1, and H460 were obtained 
from the Shanghai Institute of Thoracic Oncology (Shanghai, People’s Republic of 
China). All cell lines were cultured and maintained in Dulbecco’s modified Eagle’s 
medium (Grand Island Biological Company, Grand Island, New York) supplemented 
with 10% (v/v) heat-inactivated fetal bovine serum (Shanghai ChangDao, Bio-TECH, 
Shanghai, People’s Republic of China), 100 U/mL of penicillin, and 100 μg/mL of 
streptomycin in a humidified incubator with 5% carbon dioxide.
Growth Inhibition of Human Lung Adenocarcinoma Cells
The growth-inhibitory effects of cetuximab and endostatin alone and in combina-
tion were evaluated using a modified tetrazolium salt (MTT) assay.16 In the MTT 
assay, ~2000 viable cells were plated in 100 μL of growth medium in 96-well plates. 
After overnight incubation, varying concentrations of cetuximab (12.5, 25, and 
50 μg/mL), endostatin, and the combination of cetuximab + endostatin were added to 
the plates, and the cells were incubated with MTT for 4 days. Tetrazolium salt 
0.5 mg/mL was added to each well. The plates were incubated with the salt for 
4 hours at 37°C and the medium was removed using aspiration, leaving the dark-blue 
formazan product at the bottom of the wells. The reduced MTT product was solubi-
lized by adding 150 μL of dimethyl sulfoxide and was vortexed for 10 minutes. The 
absorbancy of each well was measured using an automated plate reader (Bio-RAD 
Laboratories, Hercules, California). All experiments were done in triplicate.
Enzyme-Linked Immunosorbent Assay
Enhanced expression of angiogenic factors VEGF17 and IL-818–20 has been detected 
in the majority of human carcinomas. We therefore used enzyme-linked immunosor-
bent assay (ELISA) to observe whether the secreted protein production of VEGF and 
IL-8 was downregulated when the cell lines were treated with cetuximab, endostatin, 
or cetuximab + endostatin. 
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The effects of combination treatment were examined using an MTT assay. The com-
bination cetuximab 12.5 μg/mL + endostatin 25 μg/mL was found to produce an inhibi-
tory ratio of ~50% in H1299, SPC-A1, and H460 cells. We treated tumor cell lines 
with cetuximab 12.5 μg/mL, endostatin 25 μg/mL, and cetuximab 12.5 μg/mL + 
endostatin 25 μg/mL in 96-well plates. After 4 days of incubation, supernatant from 
varying doses of the drugs was collected for ELISA. The concentrations of VEGF and 
IL-8 were measured using a commercially available ELISA kit according to the manu-
facturer’s instructions (Shanghai Westtang BIO-TECH, Shanghai, People’s Republic 
of China).
Western Blot Analysis
In the Western blot analysis, ~50,000 viable cells were plated in 100-mm–diameter 
dishes. For the detection of EGFR expression, the cells were collected after 4 days of 
incubation without any drugs. For the detection of expression of VEGF and IL-8, 
cetuximab 12.5 μg/mL, endostatin 25 μg/mL, and cetuximab 12.5 μg/mL + endostat- 
in 25 μg/mL were added to the dishes, and the cells were incubated with varying 
doses of the drugs for 4 days. The cells were rinsed once with ice-cold phosphate-
buffered saline and the radio-immunoprecipitation assay lysis buffer 100 μL was 
added. The cells were scraped off the dishes and incubated on ice for 30 minutes. The 
mixture was centrifuged at 12,000 rpm for 10 minutes at 4°C in preparation for 
Western blot analysis. Approximately 30 μg of proteins extracted from the tumor cells 
was loaded on an SDS/8% (w/v) polyacrylamide gel. For VEGF and IL-8, SDS/15% 
(w/v) polyacrylamide gel was used. Following electrophoresis, the proteins were trans-
ferred to a polyvinylidene fluoride membrane. After the blocking mixture was added, 
the membranes were hybridized with antibodies against VEGF (1:200 dilution; Ab-
cam Ltd., Cambridge, United Kingdom), IL-8 (1:300 dilution; Abcam Ltd.), and 
EGFR (1:250 dilution; Abcam Ltd.) in tris-buffered saline-T buffer with 5% nonfat 
dry milk overnight at 4°C. Bound antibodies were detected using antirabbit horserad-
ish peroxidase conjugated secondary antibody (Santa Cruz Biotechnology, Inc., Santa 
Cruz, California) with 1:2500 dilution and using an enhanced chemiluminescence 
system (Amersham Biosciences, Piscataway, New Jersey). Normalization of total 
loaded proteins was obtained by immunodetection of glyceraldehyde 3-phosphate 
dehydrogenase on the same blotted membrane with specific antibodies (Santa Cruz 
Biotechnology, Inc.).
Statistical Analysis
In the MTT assay, the mean difference in absorbance was compared between treat-
ments and controls using the Dunnett t test. An independent-samples t test was done 
to compare the inhibitory ratios of cetuximab + endostatin to those of cetuximab 
alone. In ELISA, the least significant differences test was used to compare the differ-
ence between cetuximab alone or endostatin alone and controls and the difference 
between cetuximab + endostatin and cetuximab alone. A difference of P < 0.05 was 
considered significant. Statistical analysis was performed using SPSS version 11.0 
(SPSS Inc., Chicago, Illinois).
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RESULTS
Epidermal Growth Factor Receptor Expression in Human Lung 
Adenocarcinoma Cells
The intensity of EGFR staining was greater in the H1299 cells than in the SPC-A1 
cells, while the expression of EGFR was lowest in the H460 cells. The intensity of 
EGFR staining was greater in the H1299 cells than in the SPC-A1 cells, while the 
expression of EGFR was lowest in the H460 cells (Figure 1).
In Vitro Cell Growth Inhibition
In vitro treatment of cell lines with cetuximab was associated with dose-dependent 
cytostasis (Table I). Compared with controls, cetuximab treatment was associated 
with significantly inhibited growth of the H1299 cell line, which had the greatest 
EGFR expression; the inhibitory ratios of cetuximab 12.5, 25, and 50 μg/mL were 
0.27, 0.35, and 0.47, respectively (all, P < 0.05). Compared with controls, cetuximab 
was associated with moderate inhibition of the growth of SPC-A1 cells (0.18, 0.26, 
and 0.40; all, P < 0.05), which had intermediate EGFR expression. The growth of the 
H460 cell line was found to be significantly less inhibited with cetuximab compared 
with that of the H1299 and H460 cell lines (inhibitory ratios, 0.17, 0.20, and 0.34; 
all, P < 0.05). The maximum inhibition observed with cetuximab was 47% after 
4 days of continuous exposure at the highest dose (50 μg/mL). Endostatin was not 
associated with significant growth inhibition of any of the cell lines.
The inhibitory ratios with cetuximab 12.5 to 50 μg/mL + endostatin 12.5 to 
50 μg/mL are summarized in Table II. The inhibitory ratios with cetuximab + 
endostatin at varying concentrations were found to be significantly greater than 
those with cetuximab alone (all, P < 0.05). The 50% inhibitory concentrations ob-
H460
EGFR
GAPDH
SPC-A1 H1299
Figure 1.  Expression of epidermal growth factor receptor (EGFR) in 3 human lung adeno-
carcinoma cell lines (H1299, SPC-A1, and H460) detected by Western blot 
analysis. The cells were treated with radio-immunoprecipitant assay lysis buffer. 
Precleared cellular lysates were separated on an SDS/8% polyacrylamide gel 
and were then transferred to a polyvinylidene fluoride membrane. The immuno-
blots were blocked in 5% nonfat dry milk for 1 hour and hybridized with the 
antibodies shown. The immunoblots were visualized using an enhanced chemi-
luminescence system (magnification, 2.5X). GAPDH = glyceraldehyde 3-phosphate 
dehydrogenase. 
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Table I. Inhibitory ratios* (IR) of treatment with cetuximab alone or endostatin alone in human lung adenocarcinoma cells.†
 Cetuximab Endostatin
 12.5 μg/mL 25 μg/mL 50 μg/mL 12.5 μg/mL 25 μg/mL 50 μg/mL
Cell Line IR P IR P IR P IR P IR P IR P
H1299 0.27 <0.001 0.35 <0.001 0.47 <0.001 0.06 0.70 0.08 0.56 0.09 0.44
SPC-A1 0.18 0.025 0.26 <0.001 0.40 <0.001 0.05 0.58 0.04 0.74 0.08 0.26
H460 0.17 <0.001 0.20 <0.001 0.34 <0.001 0.04 0.86 0.06 0.63 0.07 0.55
*Calculated as (mean absorbancecontrol – mean absorbancetreatment)/mean absorbancecontrol.
†   All P values are versus controls.
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served in the H1299, SPC-A1, and H460 cell lines all occurred with cetuximab 
12.5 μg/mL + endostatin 25 μg/mL.
Downregulation of Vascular Endothelial Growth Factor and  
Interleukin-8 in Human Lung Adenocarcinoma Cells
Secreted VEGF and IL-8 protein in the H1299 and SPC-A1 cell lines were signifi-
cantly inhibited by either cetuximab or endostatin alone (all, P < 0.05) (Table III). 
With combination treatment in the H1299 cell line, endostatin seemed to enhance 
the inhibitory effect of cetuximab on VEGF and IL-8 (687 [21] and 516 [20] pg/mL, 
respectively) compared with cetuximab alone (878 [31] and 628 [20] pg/mL; both, 
P < 0.001). In the SPC-A1 cell line, the addition of endostatin to cetuximab was as-
sociated with a significantly lower VEGF expression beyond the reduction found with 
cetuximab alone (629 [23] vs 708 [20] pg/mL; P = 0.014). The addition of endostatin 
to cetuximab, however, was not associated with significantly lower IL-8 expression be- 
yond the reduction found with cetuximab alone in the SPC-A1 cell line (480 [18] vs 
484 [29] pg/mL). In the H460 cell line, the VEGF concentrations were significant- 
ly inhibited with either drug alone (both, P < 0.001), but the addition of endostatin 
was not associated with enhancement of the inhibitory effect of cetuximab. In the 
H460 cell line, neither cetuximab nor endostatin alone was associated with signifi-
Table II.  Inhibitory ratios* (IR) of combination treatment with cetuximab + 
endostatin in human lung adenocarcinoma cells.
 IR†
Treatment  H1299 SPC-A1 H460
Cetuximab 12.5 μg/mL
  + Endostatin 12.5 μg/mL 0.32 0.23 0.24
  + Endostatin 25 μg/mL 0.51 0.47 0.49
  + Endostatin 50 μg/mL 0.57 0.56 0.53
Cetuximab 25 μg/mL
  + Endostatin 12.5 μg/mL 0.41 0.31 0.33
  + Endostatin 25 μg/mL 0.55 0.57 0.54
  + Endostatin 50 μg/mL 0.63 0.58 0.58
Cetuximab 50 μg/mL
  + Endostatin 12.5 μg/mL 0.47 0.59 0.54
  + Endostatin 25 μg/mL 0.62 0.63 0.59
  + Endostatin 50 μg/mL 0.67 0.67 0.64
P versus controls 0.003 0.001 <0.001
* Calculated as (mean absorbancecontrol – mean absorbancetreatment)/mean 
  absorbancecontrol. 
†  P < 0.05 versus cetuximab alone (t test).
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Table III.  In vitro inhibition of vascular endothelial growth factor (VEGF) and interleukin (IL)-8 with cetuximab, endostatin, and 
cetuximab + endostatin. 
   Cetuximab + 
Cell Line Cetuximab Endostatin Endostatin Control
H1299
  VEGF
    Concentration, mean (SD), pg/mL 878 (31) ↓ 1291 (41) ↓ 687 (21) ↓↓ 1583 (45)
    P versus control <0.001 <0.001 <0.001 –
    P versus cetuximab alone – – <0.001 –
  IL-8
    Concentration, mean (SD), pg/mL 628 (20) ↓ 819 (13) ↓ 516 (20) ↓↓ 866 (16)
    P versus control <0.001  0.011 <0.001 –
    P versus cetuximab alone – – <0.001 –
SPC-A1
   VEGF
    Concentration, mean (SD), pg/mL 708 (20) ↓ 882 (25) ↓ 629 (23) ↓↓ 1288 (41)
    P versus control <0.001 <0.001 <0.001 –
    P versus cetuximab alone – –  0.014 –
   IL-8
    Concentration, mean (SD), pg/mL 484 (29) ↓ 523 (17) ↓ 480 (18) ↓ 722 (40)
    P versus control <0.001 <0.001 <0.001 –
    P versus cetuximab alone – – 0.86 –
H460
   VEGF
    Concentration, mean (SD), pg/mL 789 (32) ↓ 870 (26) ↓ 780 (21) ↓ 1089 (23)
    P versus control <0.001 <0.001 <0.001 –
    P versus cetuximab alone – –  0.671 –
   IL-8
    Concentration, mean (SD), pg/mL 532 (28) 523 (17) 467 (30) ↓↓ 564 (32)
    P versus control  0.181  0.097 <0.001 –
    P versus cetuximab alone – –  0.018 –
↓ = Downregulation; ↓↓ = enhanced downregulation by endostatin.
Current Therapeutic Research
124
cantly lower IL-8 concentrations (532 [28] and 523 [17] pg/mL), but combination 
treatment was associated with significantly greater inhibition of IL-8 expression (467 
[30] pg/mL) compared with cetuximab (P = 0.018).
Similar results were obtained on Western blot analysis. Reductions in VEGF and 
IL-8 expression were found with drug treatment in the H1299 and SPC-A1 cell lines 
compared with controls. In the H460 cell line, reductions in VEGF with either drug 
alone or combination treatment were not significantly different compared with con-
trols. IL-8 concentrations were not reduced significantly with either drug alone com-
pared with controls; however, combination treatment was associated with significant 
inhibition of IL-8 expression compared with controls (Figure 2).
DISCUSSION
Angiogenesis plays a crucial role in increasing the invasiveness of, and the metastases 
in, various human carcinomas. Previous studies have found that neoplasms frequently 
have high expression of the angiogenic factors, including bFGF, VEGF, IL-8, and 
PDGF.19,21–23 The link between EGFR signaling and angiogenesis has been clearly 
identified.6–8 The monoclonal antibody cetuximab (C225), an inhibitor of EGFR, has 
been found to have downregulated angiogenic factors by blocking the EGFR signal 
pathway and to have inhibited the growth of some EGFR-overexpressing cell lines of 
various histologies, including NSCLC, both in vitro and in vivo.24–27 The present 
study characterized a panel of human lung adenocarcinoma cell lines of various EGFR 
expression using Western blot analysis. EGFR expression in the H1299 cell line was 
higher than in the SPC-A1 and H460 lines. All 3 cell lines expressed EGFR, which 
was potentially sensitive to cetuximab.
Endostatin, a 20-kDa C-terminal fragment of type XVIII collagen, was the first 
endogenous inhibitor of angiogenesis to be identified. Some experimental studies have 
found that recombinant endostatin reduced experimental tumors to a dormant 
state.11,28–30 
This study found that cetuximab was associated with a significant inhibition of the 
growth of these 3 EGFR-expressing cell lines. It appeared that cells with higher levels 
of EGFR expression were more sensitive to cetuximab. Endostatin was not associated 
with inhibition of the growth of any of the cell lines, but it was associated with a 
significantly enhanced inhibitory effect of cetuximab. Combination treatment with 
these 2 drugs was associated with a greater inhibitory effect compared with treatment 
with either drug alone.
Endothelial-stimulating growth factors (eg, VEGF31, IL-832–35) provide survival 
signals to the activated endothelial cells during angiogenesis. Based on the results 
found with either drug alone compared with the combination treatment on these 
biomarkers of angiogenesis in the present study, the additive effects of endostatin 
could be attributed to its effect on VEGF expression and, to a lesser degree, on IL-8 
expression. IL-8 expression apparently was not affected in the H460 cell line by these 
2 drugs; this finding might correlate with EGFR expression, which was much lower 
in H460 than H1299 and SPC-A1. This finding might also mean that there exists 
some unclear mechanism leading to cetuximab and endostatin resistance. 
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Figure 2.  Effects of cetuximab alone and in combination with endostatin on vascular 
endothelial growth factor (VEGF) and interleukin (IL)-8 expression in human 
lung adenocarcinoma cell lines (A) H1299 and (B) SPC-A1. Lane 1: cells cul-
tured for 4 days as the control; lane 2: cells treated for 4 days with cetuximab 
12.5 μg/mL; lane 3: cells treated for 4 days with endostatin 25 μg/mL; and 
lane 4: cells treated for 4 days with cetuximab 12.5 μg/mL + endostatin 
25 μg/mL. Cells were treated with radio-immunoprecipitant assay lysis buffer. 
Precleared cellular lysates were separated on an SDS/15% polyacrylamide gel 
and were then transferred to a polyvinylidene fluoride membrane. The immuno-
blots were blocked in 5% nonfat dry milk for 1 hour and hybridized with the 
antibodies shown. The immunoblots were visualized using an enhanced chemi-
luminescence system (magnification, 2X). GAPDH = glyceraldehyde 3-phosphate 
dehydrogenase. 
(continued) 
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CONCLUSIONS
Data from this study suggest that cetuximab treatment had a growth-inhibitory effect 
in vitro that was attributable to direct blockade of the EGFR-dependent mitogenic 
pathway. The drug was associated with inhibited human lung adenocarcinoma cell 
line growth and with reduced expression of VEGF and IL-8, which are the biomarkers 
of angiogenesis. Endostatin was not associated with downregulated expression of 
VEGF and IL-8, although a direct inhibitory effect on growth of the H1299, SPC-A1, 
and H460 cell lines was apparent. Results with combination treatment suggested that 
endostatin might enhance the antiangiogenic and antitumor activity of cetuximab. 
Further studies are needed.
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Figure 2  (continued). Effects of cetuximab alone and in combination with endostatin 
on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 expression 
in human lung adenocarcinoma cell line (C) H460. Lane 1: cells cultured for 
4 days as the control; lane 2: cells treated for 4 days with cetuximab 12.5 μg/mL; 
lane 3: cells treated for 4 days with endostatin 25 μg/mL; and lane 4: cells 
treated for 4 days with cetuximab 12.5 μg/mL + endostatin 25 μg/mL. Cells 
were treated with radio-immunoprecipitant assay lysis buffer. Precleared cellular 
lysates were separated on an SDS/15% polyacrylamide gel and were then trans-
ferred to a polyvinylidene fluoride membrane. The immunoblots were blocked in 
5% nonfat dry milk for 1 hour and hybridized with the antibodies shown. The im-
munoblots were visualized using an enhanced chemiluminescence system (mag-
nification, 2X). GAPDH = glyceraldehyde 3-phosphate dehydrogenase.  
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